Zentalis Pharmaceuticals Reports Third Quarter 2025 Financial Results and Operational Progress

Impact · against what's priced in

Zentalis provides a positive update on its cash position and clinical timelines, ensuring the company can reach its critical 2026 data readout without immediate dilution. The confirmation of an accelerated approval pathway for azenosertib in Cyclin E1-positive PROC enhances the long-term NPV of the lead asset.

ZNTL+0.50

No priced-in read yet